SR9009
Also known as: Stenabolic
Status
No approved product. No FDA-approved labeling exists. Not an approved medicine in the United States; its status as a US dietary ingredient has not been verified for this entry.
What it is
A circadian-pathway molecule with very poor oral availability in studies.
What published research measured
Frequently sold alongside the selective androgen receptor modulators but mechanistically unrelated: it is an agonist of the REV-ERB nuclear receptors, part of the circadian machinery. The 2012 Nature paper reporting improved endurance and metabolic changes in mice is the origin of its reputation. The finding that matters most is one the marketing never carries — subsequent pharmacokinetic work established that SR9009 has essentially no oral bioavailability. The mouse experiments that generated the endurance results used injected administration; an orally taken capsule cannot reproduce the exposure those results depend on. Independent work has also questioned whether some of the reported effects are mediated by REV-ERB at all. No published human trial was identified. Prohibited at all times in sport under the 2026 WADA Prohibited List (S4.4.1, metabolic modulators).
Source
Solt et al. 2012, Nature — REV-ERB agonist metabolic and endurance effects in mice · Subsequent pharmacokinetic work establishing negligible oral bioavailability · WADA 2026 Prohibited List, class S4.4.1 (metabolic modulators)
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.